Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10477627 | 0.98 | — | — | |
| SCHEMBL17574133 | 0.86 | — | — | |
| SCHEMBL19699898 | 0.84 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL10477628 | 0.80 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL17558776 | 0.77 | TSHR (0.36) | — | |
| SCHEMBL10477632 | 0.75 | TSHR (0.37) | — | |
| SCHEMBL10477606 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL1549585 | 0.73 | FFAR3 (0.36) | — | |
| SCHEMBL10477629 | 0.72 | PPARD (0.39) | SMN1; SMN2 | |
| SCHEMBL28604147 | 0.71 | SMN1; SMN2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189054-B1 | (1-FLUORO-CYCLOHEX-1-YL)-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| US-20160075711-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| WO-2016037026-A1 | CYCLOHEXYL-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-03-10 | — | — | WO | disclosed |
| US-4808734-A | 16-cycloalkyl-7-fluoro-prostacyclins | HOFFMANN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | SMN1; SMN2 3188/4885 |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | IDO1, IDO2, INMT | SMN1; SMN2 3188/4885 |
| US-20160075711-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | SMN1; SMN2 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.